Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (1) · (multiple, generic dominant) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Paxil (IR), Paxil CR (controlled-release), Brisdelle (low-dose for menopausal vasomotor symptoms), Pexeva (paroxetine mesylate) (1)

2C-x series (1) · Analgesic (2) · Opioid (2) · Phenethylamine (1) · Prodrug (1) · Psychedelic (1) · [[:Category:Antidepressants|Antidepressant]] (1) · [[:Category:Anxiolytics|Anxiolytic]] (1) · [[:Category:SSRIs|Selective serotonin reuptake inhibitor (SSRI)]] (1)

None (1) · 5-HT2A partial agonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"', '"`UNIQ--vote-00000029-QINU`"', '"`UNIQ--vote-0000002A-QINU`"' (1)

None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · MDD/GAD: 20 mg PO once daily. Panic disorder: 10 mg titrating to 40 mg. OCD: 20 mg titrating to 40-60 mg. CR: 25 mg/day. Brisdelle: 7.5 mg at bedtime for hot flashes (1)

None (2) · IR tablets 10, 20, 30, 40 mg; CR tablets 12.5, 25, 37.5 mg; oral suspension 10 mg/5 mL; Brisdelle capsules 7.5 mg (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · 50 mg/day (IR); 62.5 mg/day (CR); 60 mg/day (OCD) (1)

None (1) · insufflated (1) · Oral (2) · PO (only formulation marketed in the US). (1) · PR (1)

None (1) · 30–60 min (PO) (1) · 45-75 min (oral) (1) · Antidepressant effect emerges over 1-2 weeks (1)

None (1) · 24 hours (once-daily dosing) (1) · 4-8 h (1) · 4–6 hours (1)

None (1) · 2.5–3 hours (1) · Not well characterized (1) · ~21 hours (with nonlinear pharmacokinetics from CYP2D6 autoinhibition)'"`UNIQ--ref-0000002B-QINU`"' (1)

None (1) · Highly variable due to saturable first-pass metabolism'"`UNIQ--ref-0000002C-QINU`"' (1) · Not well characterized (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (1) · '''Among the least preferred SSRIs in pregnancy.''' Observational signal for cardiac malformations (atrial and ventricular septal defects) with first-trimester exposure, and the most severe neonatal adaptation syndrome of any SSRI with third-trimester exposure'"`UNIQ--ref-0000002D-QINU`"' (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Not established (1)

None (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-0000002E-QINU`"' (1)